Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Apr 18 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for the Estradiol Transdermal System. This product is indicated for the prevention of postmenopausal osteoporosis and will be manufactured at their facility in Moraiya, Ahmedabad. The press release highlights that the drug had annual sales in the United States and adds to Zydus's extensive portfolio of approvals.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases